HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Comparative clinical study of SF-SP therapy and SF-SP plus BH-AC therapy in gastrointestinal cancer. Tokyo Cancer Chemotherapy Cooperative Study Group].

Abstract
SF-SP which contains sustained release granules of tegafur has been reported to be effective for gastrointestinal and breast cancer. HB-AC, which is an anti-leukemic agent, is known to have considerable activity against a variety of transplanted solid tumors in rats and mice. A comparative clinical study was therefore conducted by randomized controlled trial on the two different chemotherapies, involving as SF-SP group and as SF-SP plus BH-AC group. Among 58 patients, 42 were evaluable for response (SF-SP: 20/30, SF-SP plus BH-AC: 22/28). The partial response rate of SF-SP was 15.0% (3/20) and that of SF-SP plus BH-AC was 13.6% (3/22). The toxicity rates of SF-SP and SF-SP plus BH-AC were 33.3% (10/30) and 36.0% (9/25), respectively. These results indicated that the two therapies were similar in both response and toxicity rates. However, the response appeared faster in the case of SF-SP plus BH-AC therapy than in that of SF-SP therapy.
AuthorsT Izumi, M Yoshida, T Kamaro, H Sato
JournalGan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 13 Issue 11 Pg. 3215-20 (Oct 1986) ISSN: 0385-0684 [Print] Japan
PMID3096218 (Publication Type: Clinical Trial, Comparative Study, English Abstract, Journal Article, Randomized Controlled Trial)
Chemical References
  • Delayed-Action Preparations
  • Cytarabine
  • Tegafur
  • enocitabine
Topics
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Colonic Neoplasms (drug therapy)
  • Cytarabine (administration & dosage, analogs & derivatives)
  • Delayed-Action Preparations
  • Female
  • Humans
  • Liver Neoplasms (drug therapy)
  • Male
  • Middle Aged
  • Splenic Neoplasms (drug therapy)
  • Stomach Neoplasms (drug therapy)
  • Tegafur (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: